Ratings GSK plc

Equities

GSK

GB00BN7SWP63

Market Closed - London Stock Exchange Other stock markets 11:35:29 2023-12-05 am EST			5-day change	1st Jan Change
1,439.6 ^GBX	-1.09%		+1.97%	+0.14%

Dec. 05	Merck KGaA suffers major blow as MS drug fails in late-stage trials	RE
Dec. 05	Anything is possible

Summary

The company has strong fundamentals. More than 70% of companies have a lower mix of growth, profitability, debt and visibility.
The company's Refinitiv ESG score, based on a ranking of the company relative to its industry, comes out particularly well.

Strengths

Before interest, taxes, depreciation and amortization, the company's margins are particularly high.
Margins returned by the company are among the highest on the stock exchange list. Its core activity clears big profits.
With a P/E ratio at 10.72 for the current year and 10.4 for next year, earnings multiples are highly attractive compared with competitors.
The company has a low valuation given the cash flows generated by its activity.
Over the last 4 months, analysts have significantly revised upwards the company's estimated sales.
The group usually releases upbeat results with huge surprise rates.

Weaknesses

The company's earnings growth outlook lacks momentum and is a weakness.
In relation to the value of its tangible assets, the company's valuation appears relatively high.
The price targets of analysts who cover the stock differ significantly. This implies difficulties in evaluating the company and its business.

Ratings chart - Surperformance

Chart ESG Refinitiv

Sector : Pharmaceuticals

	1st Jan change	Capi.	ESG Refinitiv
GSK PLC	+0.14%	73 933 M $	B
ELI LILLY AND COMPANY	+60.77%	529 B $	C+
NOVO NORDISK A/S	+46.50%	444 B $	B
JOHNSON & JOHNSON	-10.25%	382 B $	C+
MERCK & CO., INC.	-4.25%	269 B $	B-
ABBVIE INC.	-10.54%	255 B $	C+
ROCHE HOLDING AG	-13.61%	231 B $	A+
NOVARTIS AG	+1.76%	200 B $	B-
ASTRAZENECA PLC	-9.57%	198 B $	B+
PFIZER, INC.	-43.23%	164 B $	C+

Investor Rating

Trading Rating

ESG Refinitiv

Financials

Sales growth

Earnings Growth

EBITDA / Sales

Profitability

Finances

Valuation

P/E ratio

EV / Sales

Price to Book

Price to Free Cash Flow

Yield

Momentum

1 year Revenue revision

4 months Revenue revision

7 days Revenue revision

1 year EPS revision

4 months EPS revision

Consensus

Analyst Opinion

Potential Price Target

4m Target Price Revision

4m Revision of opinion

12m Revision of opinion

Business Predictability

Analyst Coverage

Divergence of Estimates

Divergence of analysts' opinions

Divergence of Target Price

Earnings quality

Environment

Emissions

Innovation

Use of resources

Governance

CSR Strategy

Management

Shareholders

Controversy

Technical analysis

ST Timing

MT Timing

LT Timing

RSI

Bollinger Spread

Unusual volumes